Companies working on Cannabinoids for treatment of Disease: GW Pharmaceuticals Gold Seal (San Francisco based cannabis brand that specializes in high end flower).
Introduction:
Two cannabinoid receptors have been identified so far, cannabinoid receptor 1 (CB1) from rat and human brain cDNA libraries, and cannabinoid receptor 2 (CB2) from human leukemic cell line (HL60) cDNA library Gerard et al., 1991; Matsuda et al., 1990 CB1 and CB2 are . (Bruan et al., “Regulation of interleukin-12 production by G-protein-coupled receptors” 3(2) (2001, pages 99-107)
The peripheral cannabinoid receptor (CB2) is a G protein coupled receptor that is both positively and negatively couples to the mitogen-activated protein kinase (MAPK) and cAMP pathways, respectively, through a Bordetella pertussis toxin-senstive G protein. (Bouaboula et et., “Gi Protein Modulation Induced by a Selective Inverse Agonist for Periopheral Cannabinoid Receptor CB2: Implication for Intracellular Signalization Cross-Regulation.)
The CB1 receptor is abundant in the brain and contributes to learning, memory, and cognitive processes which are interrupted early in the course of AD. To the contrary, CB2 receptor expression is ore limited and has been anatomically found in neurons within the brainstem.
Encodcannabinoid receptors, CB1 and CB2, have been reported to interact with delta9-tetrahydrocannabinol (THC) isolated form the Canabis sativa plant. In addition, it has been reported that Dronabinol, an oil-based solution of delta9-THC, improved the disturbed behavior and stimulates appetite in AD patients. Accumulated evidence also suggests antioxidants having anti-inflammatory and neuroprotective roles. (Cao, US 11,065,225)
Agonists of the Cannabinoid Receptors
Agonists of the central cannabinoid receptor CB1 have been used for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma. (U.S. Patent No. 6,525,087). Activation of the CB2 receptor has been shown to result in suppression of the immune system. (U.S. Patent No. 6,166,066)
Antagonists of the Cannabinoid Receptors
In addition to cannabimimetic agonists, receptor antagonists have also been described. The first of these was the orally active antagonist with high affinity for CB1 termed SR141616A. This compound was shown in rat brain membrane preparations (CB1 rich) to inhibit the binding of various receptor agonists with a Ki in the nM range while binding in splenocyte membranes (CB2 rich) was inhibited in the uM range. Rinaldi-Carmona M. et al., “SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350: 240-244. An antagonist for CB2 has also been described and termed SR144528.
CB1 Inhibitors and Weight Loss:
Nearly 20 years after the FDA’s rejection of what would have been the first approved drug in the class, a new generation of CB1 receptor inhibitors is undergoing early- and mid-stage clinical trials for the treatment of obesity. Novo Nordisk, Corbus Pharmaceuticals and Skye Bioscience are all hoping the improved safety profiles of their therapies will lead to a new method of treating the disease. Rimonabant, the first-in-class cannabinoid receptor 1 (CB1) receptor antagonist from Sanofi, which was approved in Europe for weight loss, worked to suppress appetite by blocking endocannabinoid receptors in the brain. While rimonabant successfully helped patients lose weight, it greatly increased instances of depression, anxiety and suicidality in patients. It was withdrawn as a result of these side effects. Now, Novo, Corbus and Skye are hoping to bring a version to the market that is safer and just as effective as the early class by avoiding the CB1 receptors in the brain. Instead, these compounds will work on peripheral receptors throughout the body, which will also allow for higher dosing. There is evidence that this particular target being found in the peripheral tissues, especially in adipose tissues and important organs like the liver, muscles and even the GI track. Peripherally restricted CB1-targeting drugs, such as Skye’s nimacimab, Corbus’s CRB-913 and Novo’s monlunabant do not cross the blood-brain barrier, therefore reducing the chance of neuropsychiatric effects such as depression. (see “Can CB1 inhibitors make a come back in obesity” Biospace, October 7, 2024).
Inverse Agonists of the Cannabinoid Receptors
Besides inhibiting the binding and function of cannabimimetic agents, the SR compounds act as inverse agonists in cell models displaying constitutive CB1 or CB2 activity. Thus, in certain cell types, treatment with SR compounds alone may cause changes in biological function by not only blocking the action of agonist, but also suppressing constitutive activity of CBRs as well as the activity of other G protein-coupled receptors.Bouaboula M et al., “Gi protein modulation induced by a selective inverse agonist for the periopheral cannabinoid receptor CB2: Implication for intracellular signalization cross regulation.” Mol Pharmacol 55:473-480, 1999